Q4 Earnings Overview for Life Sciences Tools & Services Sector
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy TXG?
Source: Yahoo Finance
- Sector Performance: The life sciences tools and services sector reported Q4 revenues that exceeded analysts' expectations by 1.7%, highlighting its critical role in biotech and pharmaceutical R&D, despite challenges related to reliance on large pharmaceutical companies' R&D budgets.
- 10x Genomics Strong Results: 10x Genomics reported revenues of $166 million, flat year-on-year, but exceeded analysts' expectations by 4.3%, showcasing the company's robust performance in single-cell analysis, with its stock rising 24.1% since the earnings report.
- Illumina Maintains Leadership: Illumina's revenues reached $1.16 billion, up 5% year-on-year, beating expectations by 3.2%; however, the market reacted negatively with a 3.8% stock decline, despite its full-year guidance exceeding analyst forecasts, indicating ongoing competitiveness in genomics.
- Fortrea's Weak Performance: Fortrea reported revenues of $660.5 million, down 5.2% year-on-year, falling short of analyst expectations, and its full-year guidance significantly missed forecasts, leading to a 3.9% drop in stock price, reflecting challenges in the clinical research services sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 20.910
Low
9.00
Averages
13.00
High
18.00
Current: 20.910
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Q4 Earnings Overview for Life Sciences Tools & Services Sector
- Sector Performance: The life sciences tools and services sector reported Q4 revenues that exceeded analysts' expectations by 1.7%, highlighting its critical role in biotech and pharmaceutical R&D, despite challenges related to reliance on large pharmaceutical companies' R&D budgets.
- 10x Genomics Strong Results: 10x Genomics reported revenues of $166 million, flat year-on-year, but exceeded analysts' expectations by 4.3%, showcasing the company's robust performance in single-cell analysis, with its stock rising 24.1% since the earnings report.
- Illumina Maintains Leadership: Illumina's revenues reached $1.16 billion, up 5% year-on-year, beating expectations by 3.2%; however, the market reacted negatively with a 3.8% stock decline, despite its full-year guidance exceeding analyst forecasts, indicating ongoing competitiveness in genomics.
- Fortrea's Weak Performance: Fortrea reported revenues of $660.5 million, down 5.2% year-on-year, falling short of analyst expectations, and its full-year guidance significantly missed forecasts, leading to a 3.9% drop in stock price, reflecting challenges in the clinical research services sector.
See More
Analysis of Options Trading for 10x Genomics Inc
- Options Selling Risks: Selling put options does not provide investors with the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, meaning actual gains only occur if the stock price falls by 32.1%.
- Yield Analysis: Selling the $15 put option under current market conditions offers a 20.6% annualized return, but this is only realized if the stock price drops to $13.55, highlighting the complex relationship between risk and reward in options trading.
- Volatility Consideration: The trailing twelve-month volatility for 10x Genomics Inc is calculated at 70%, and when combined with fundamental analysis, it can assist investors in determining whether selling puts is worthwhile in the current market environment.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
UBS Increases Target Price for 10X Genomics Inc. to $20, Up from $14
- Price Increase Announcement: Genomics Inc. has raised its target price from $14 to $20.
- Market Impact: This adjustment reflects a positive outlook on the company's performance and potential growth in the genomics sector.
See More
10x Genomics Q4 Earnings Beat Expectations
- Earnings Highlights: 10x Genomics reported a Q4 GAAP EPS of -$0.13, beating expectations by $0.08, indicating improved financial management despite still being in the negative territory.
- Revenue Growth: The company achieved Q4 revenue of $166 million, a 0.6% year-over-year increase, surpassing market expectations by $5.65 million, suggesting sustained acceptance of its products in the market.
- Future Outlook: 10x Genomics expects full-year 2026 revenue to range between $600 million and $625 million, although below the consensus of $611.77 million, it still reflects confidence in future growth, particularly with projected growth of 0% to 4% when excluding non-recurring license and royalty revenues from 2025.
- Market Reaction: Despite the earnings beat, shares fell by 3%, indicating market concerns regarding the company's growth potential, especially in light of weak spending in the U.S.
See More
10x Genomics Set to Release Q4 Earnings on February 12
- Earnings Announcement: 10x Genomics is scheduled to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at -$0.04 and revenue expected at $160.35 million, reflecting a 2.8% year-over-year decline.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen three upward revisions with no downward adjustments, indicating a growing confidence among analysts regarding the company's profitability.
- Revenue Estimate Adjustments: The revenue estimates have experienced ten upward revisions and one downward revision, suggesting a generally optimistic outlook for future revenue growth despite the company's overall sales performance being weaker.
- Market Performance Insights: While 10x Genomics' products are well-received, the weakness in U.S. spending continues to stifle growth, highlighting the challenges and opportunities the company faces in the current economic landscape.
See More
10x Genomics Fuels Creation of Major Cancer Dataset with AI Integration
- Dataset Construction: PharosAI will utilize 10x Genomics' Xenium spatial platform to create one of the world's largest multimodal cancer datasets, backed by £18.9 million in government funding, aimed at accelerating early diagnosis and precision therapies.
- Technical Collaboration: The research consortium comprises four leading UK institutions, combining clinical expertise with advanced technologies, planning to transform thousands of clinical tissue samples into high-resolution datasets to drive breakthroughs in cancer research.
- AI Model Application: By integrating genomic, transcriptomic, and spatial biology data, PharosAI will develop custom AI models that reveal hidden patterns in cancer research, thereby enhancing patient care and treatment outcomes.
- Open Data Sharing: The initiative will ensure secure access to datasets for a broad community of researchers and innovators, positioning the UK at the forefront of AI-driven cancer research and advancing the field of precision medicine.
See More
Q4 Earnings Overview for Life Sciences Tools & Services Sector
- Sector Performance: The life sciences tools and services sector reported Q4 revenues that exceeded analysts' expectations by 1.7%, highlighting its critical role in biotech and pharmaceutical R&D, despite challenges related to reliance on large pharmaceutical companies' R&D budgets.
- 10x Genomics Strong Results: 10x Genomics reported revenues of $166 million, flat year-on-year, but exceeded analysts' expectations by 4.3%, showcasing the company's robust performance in single-cell analysis, with its stock rising 24.1% since the earnings report.
- Illumina Maintains Leadership: Illumina's revenues reached $1.16 billion, up 5% year-on-year, beating expectations by 3.2%; however, the market reacted negatively with a 3.8% stock decline, despite its full-year guidance exceeding analyst forecasts, indicating ongoing competitiveness in genomics.
- Fortrea's Weak Performance: Fortrea reported revenues of $660.5 million, down 5.2% year-on-year, falling short of analyst expectations, and its full-year guidance significantly missed forecasts, leading to a 3.9% drop in stock price, reflecting challenges in the clinical research services sector.
See More
Analysis of Options Trading for 10x Genomics Inc
- Options Selling Risks: Selling put options does not provide investors with the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, meaning actual gains only occur if the stock price falls by 32.1%.
- Yield Analysis: Selling the $15 put option under current market conditions offers a 20.6% annualized return, but this is only realized if the stock price drops to $13.55, highlighting the complex relationship between risk and reward in options trading.
- Volatility Consideration: The trailing twelve-month volatility for 10x Genomics Inc is calculated at 70%, and when combined with fundamental analysis, it can assist investors in determining whether selling puts is worthwhile in the current market environment.
- Market Trading Dynamics: On Tuesday afternoon, the put volume among S&P 500 components reached 1.01 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
UBS Increases Target Price for 10X Genomics Inc. to $20, Up from $14
- Price Increase Announcement: Genomics Inc. has raised its target price from $14 to $20.
- Market Impact: This adjustment reflects a positive outlook on the company's performance and potential growth in the genomics sector.
See More
10x Genomics Q4 Earnings Beat Expectations
- Earnings Highlights: 10x Genomics reported a Q4 GAAP EPS of -$0.13, beating expectations by $0.08, indicating improved financial management despite still being in the negative territory.
- Revenue Growth: The company achieved Q4 revenue of $166 million, a 0.6% year-over-year increase, surpassing market expectations by $5.65 million, suggesting sustained acceptance of its products in the market.
- Future Outlook: 10x Genomics expects full-year 2026 revenue to range between $600 million and $625 million, although below the consensus of $611.77 million, it still reflects confidence in future growth, particularly with projected growth of 0% to 4% when excluding non-recurring license and royalty revenues from 2025.
- Market Reaction: Despite the earnings beat, shares fell by 3%, indicating market concerns regarding the company's growth potential, especially in light of weak spending in the U.S.
See More
10x Genomics Set to Release Q4 Earnings on February 12
- Earnings Announcement: 10x Genomics is scheduled to announce its Q4 2023 earnings on February 12 after market close, with consensus EPS estimated at -$0.04 and revenue expected at $160.35 million, reflecting a 2.8% year-over-year decline.
- Earnings Estimate Revisions: Over the past three months, EPS estimates have seen three upward revisions with no downward adjustments, indicating a growing confidence among analysts regarding the company's profitability.
- Revenue Estimate Adjustments: The revenue estimates have experienced ten upward revisions and one downward revision, suggesting a generally optimistic outlook for future revenue growth despite the company's overall sales performance being weaker.
- Market Performance Insights: While 10x Genomics' products are well-received, the weakness in U.S. spending continues to stifle growth, highlighting the challenges and opportunities the company faces in the current economic landscape.
See More
10x Genomics Fuels Creation of Major Cancer Dataset with AI Integration
- Dataset Construction: PharosAI will utilize 10x Genomics' Xenium spatial platform to create one of the world's largest multimodal cancer datasets, backed by £18.9 million in government funding, aimed at accelerating early diagnosis and precision therapies.
- Technical Collaboration: The research consortium comprises four leading UK institutions, combining clinical expertise with advanced technologies, planning to transform thousands of clinical tissue samples into high-resolution datasets to drive breakthroughs in cancer research.
- AI Model Application: By integrating genomic, transcriptomic, and spatial biology data, PharosAI will develop custom AI models that reveal hidden patterns in cancer research, thereby enhancing patient care and treatment outcomes.
- Open Data Sharing: The initiative will ensure secure access to datasets for a broad community of researchers and innovators, positioning the UK at the forefront of AI-driven cancer research and advancing the field of precision medicine.
See More
